Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cefepime/nacubactam and aztreonam/nacubactam versus best available therapy for carbapenem-resistant Enterobacterales infections
CTR20233005Phase 3Completed
- Sponsor
- NA/ 上海复星医药产业发展有限公司
- Start
- Sep 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nacubactam, cefepime, aztreonam in complicated urinary tract infection (cUTI), acute pyelonephritis, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), sponsored by NA/ 上海复星医药产业发展有限公司. Started Sep 2023; status: completed.
02
Drugs
Nacubactamcefepimeaztreonam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on CTR20233005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233005.